vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤Phase 3 CATT1 enrollment completed with 166 participants; topline results expected mid 2027
- ➤Hybrid CATT1 Phase 2a trial randomized its first participant using closed-loop insulin systems
- ➤FDA granted HPPD Orphan Drug Designation for potential sickle cell disease treatment
- ➤Cash and equivalents totaled $77.2 million as of September 30, 2026
- ➤Third-quarter net loss widened to $11.6 million, or $0.94 per share
Expert Statements
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027.”
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“In October we also randomized the first participant in Hybrid CATT1, our Phase 2a study of cadisegliatin in people with T1D who use hybrid closed-loop insulin delivery systems.”
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“As the experts at our KOL event made clear, hypoglycemia and its broader impact on blood glucose control remain a persistent burden for people with T1D even with the most advanced insulin delivery technology, and cadisegliatin aims to address exactly that.”
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“We also continue to make important progress in our broader portfolio of highly differentiated small molecule drug candidates.”
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“The FDA recently granted Orphan Drug Designation for HPPD, which has shown promising activity in preclinical models of sickle cell disease.”
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“This designation strengthens our ability to advance partnering discussions for this program and provides another opportunity to create value for shareholders.”
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027
Randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems
Get started
Create a free account to read the full story.